Table 2.
DAPA-CKD trial participant demographics and baseline clinical chemistry according to baseline diabetes status (full analysis set)
| Characteristic | Overall | With T2D | Without T2D |
|---|---|---|---|
| (N = 4304) | (n = 2906) | (n = 1398) | |
| Age (years), mean (SD) | 61.8 (12.1) | 64.4 (9.7) | 56.4 (14.6) |
| ≤65 years, n (%) | 2486 (57.8) | 1507 (51.9) | 979 (70.0) |
| >65 years, n (%) | 1818 (42.2) | 1399 (48.1) | 419 (30.0) |
| Gender, n (%) | |||
| Male | 2879 (66.9) | 1941 (66.8) | 938 (67.1) |
| Female | 1425 (33.1) | 965 (33.2) | 460 (32.9) |
| Race, n (%) | |||
| White | 2290 (53.2) | 1541 (53.0) | 749 (53.6) |
| Black | 191 (4.4) | 137 (4.7) | 54 (3.9) |
| Asian | 1467 (34.1) | 932 (32.1) | 535 (38.3) |
| American Indian/Alaska native | 136 (3.2) | 111 (3.8) | 25 (1.8) |
| Other | 220 (5.1) | 185 (6.4) | 35 (2.5) |
| Region, n (%) | |||
| Asia | 1346 (31.3) | 841 (28.9) | 505 (36.1) |
| Europe | 1233 (28.7) | 771 (26.5) | 462 (33.0) |
| North America | 813 (18.9) | 623 (21.4) | 190 (13.6) |
| Latin/South America | 912 (21.2) | 671 (23.1) | 241 (17.2) |
| Blood pressure (mmHg), mean (SD) | |||
| Systolic | 137.1 (17.4) | 139.2 (17.3) | 132.6 (16.7) |
| Diastolic | 77.5 (10.5) | 76.5 (10.1) | 79.6 (10.9) |
| Systolic blood pressure categories, n (%) | |||
| >130 mmHg | 2762 (64.2) | 2033 (70.0) | 729 (52.1) |
| >140 mmHg | 1684 (39.1) | 1273 (43.8) | 411 (29.4) |
| Mean BMI (kg/m2) | n = 4296 | n = 2899 | n = 1397 |
| 29.5 | 30.3 | 27.9 | |
| HbA1c | n = 4284 | n = 2893 | n = 1391 |
| %, mean (SD) | 7.1 (1.7) | 7.8 (1.7) | 5.6 (0.4) |
| mmol/mol, mean (SD) | 54 (19) | 62 (19) | 38 (4) |
| Haemoglobin (g/L), mean (SD) | n = 4278 | n = 2892 | n = 1386 |
| 128.3 (18.1) | 125.9 (17.9) | 133.1 (17.6) | |
| Serum creatinine (mg/dL), mean (SD) | 1.7 (0.5) | 1.6 (0.5) | 1.8 (0.5) |
| eGFR (mL/min/1.73 m2), mean (SD) | 43.1 (12.4) | 43.8 (12.6) | 41.7 (11.7) |
| eGFR categories(mL/min/1.73 m2), n (%) | |||
| ≥60 | 454 (10.5) | 348 (12.0) | 106 (7.6) |
| 45–59 | 1328 (30.9) | 918 (31.6) | 410 (29.3) |
| 30–44 | 1898 (44.1) | 1239 (42.6) | 659 (47.1) |
| <30 | 624 (14.5) | 401 (13.8) | 223 (16.0) |
| Baseline UACR (mg/g), median | 949.3 | 1016.5 | 861.0 |
| Baseline median UACR categories, n (%) | |||
| <30 mg/g (Stage A1) | 1 (0.0) | 1 (0.0) | 0 (0.0) |
| 30–300 mg/g (Stage A2) | 444 (10.3) | 308 (10.6) | 136 (9.7) |
| >300 mg/g (Stage A3) | 3859 (89.7) | 2597 (89.4) | 1262 (90.3) |